Hypoparathyroidism - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Hypoparathyroidism - Pipeline Review, H2 2018’, provides an overview of the Hypoparathyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypoparathyroidism

- The report reviews pipeline therapeutics for Hypoparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hypoparathyroidism therapeutics and enlists all their major and minor projects

- The report assesses Hypoparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hypoparathyroidism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ascendis Pharma A/S

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

GC Pharma

Shire Plc

Ascendis Pharma A/S

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

GC Pharma

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoparathyroidism - Overview

Hypoparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoparathyroidism - Overview

Hypoparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoparathyroidism - Companies Involved in Therapeutics Development

Ascendis Pharma A/S

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

GC Pharma

Shire Plc

Hypoparathyroidism - Drug Profiles

ACP-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-6272K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

parathyroid hormone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCO-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem cell Therapy for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoparathyroidism - Dormant Projects

Hypoparathyroidism - Product Development Milestones

Featured News & Press Releases

Jun 06, 2018: Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism

May 22, 2018: Shire Announces New Hypoparathyroidism Data at the 2018 European Congress of Endocrinology

May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

Apr 09, 2018: Shire’s Natpar Rejects For Use Within NHS Scotland

Mar 20, 2018: New Data Presented at the Endocrine Society’s 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism

Mar 19, 2018: Ascendis Pharma Announces Posters on Rare Disease Pipeline Programs at ENDO 2018

Mar 12, 2018: Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society’s 2018 Annual Meeting

Jan 08, 2018: Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH

Sep 26, 2017: Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

Sep 15, 2017: Extend Biosciences Is Awarded A Phase II SBIR Grant From NIDDK

Sep 05, 2017: Ascendis Pharma Announces Presentations on TransCon PTH at Upcoming Medical Conferences

May 19, 2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology

Apr 26, 2017: Shire Granted EU Conditional Marketing Authorization for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO 2017

Feb 28, 2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO 2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypoparathyroidism, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by ...

List of Tables

Number of Products under Development for Hypoparathyroidism, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H2 2018

Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Hypoparathyroidism - Pipeline by Eli Lilly and Co, H2 2018

Hypoparathyroidism - Pipeline by Entera Bio Ltd, H2 2018

Hypoparathyroidism - Pipeline by GC Pharma, H2 2018

Hypoparathyroidism - Pipeline by Shire Plc, H2 2018

Hypoparathyroidism - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Hypoparathyroidism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Hypoparathyroidism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports